Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the diseases caused by transthyretin (TTR) amyloidosis (ATTR). Co.'s product candidate, AG10, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. Co.'s approach to the treatment of ATTR is designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a rescue mutation because it has been shown to prevent ATTR in individuals carrying pathogenic, or disease-causing, mutations in the TTR gene.